First SYNGAP1 UK Family Meet Up

August 10th, 2019

The Patrick Wild Centre was excited to host the first UK SYNGAP1 Family Meet Up in June 2019!  Families from around the UK and other parts of Europe came together in Edinburgh for a day of presentations about SYNGAP1 and neurodevelopmental disorders more generally.  Distinguished speakers from many different National Health Service, university and charitable organisations shared their expertise.  They covered everything from laboratory science SYNGAP1 studies to the SYNGAP1 Syndrome in people, the mapping out of SYNGAP1 clinical research …

Launch of the Neuro-GD Study

June 21st, 2019

Dr Andy Stanfield is pleased to announce the launch of the Neuro-GD study which aims to better understand the clinical features of people with genetic conditions associated with intellectual disability and autism.  The initial focus is on SYNGAP1 related intellectual disability and fragile X syndrome but more conditions will be added. For more information click here.

Statin may be used to treat Fragile X Syndrome

June 9th, 2019

Co-Director of the Patrick Wild Centre Professor Peter Kind and colleagues have recently published a study showing that a drug named lovastatin, which is commonly used to lower cholesterol, corrected learning and memory problems in rats with a form of Fragile X Syndrome. Rats were treated with the drug for four weeks during infancy, but the benefits persisted for months afterwards. Fragile X Syndrome is one of the most common genetic causes of intellectual disability, and is often associated with …